Skip to main content

Market Overview

Barclays Cuts Charles River Labs, Sees Lack Of Demand Proof Over Long-Term

Share:

In a report published Friday, Barclays analyst Douglas D. Tsao downgraded the rating on Charles River Laboratories (NYSE: CRL) from Equal Weight to Underweight, while maintaining the price target at $60. The analyst believes that the current stock valuation has greater downside risk than upside potential.

"CRL has enjoyed a strong run based on the rebound in demand for preclinical services, although we continue to see secular challenges to in vivo testing creating greater risk for the DSA and RMS businesses than the market generally discounts," Tsao stated.

The analyst expressed concern regarding the company's organic earnings growth capabilities, despite the continuing R&D productivity. Although Charles River's management has expressed commitment to protecting margins while bringing Shrewsbury back online, the analyst believes that any meaningful upside to numbers would be limited at this time.

"Also, we expect other preclinical players to also add capacity which will at a minimum push out pricing power and could reintroduce unfavorable competitive dynamics," Tsao elaborated, while expressing concern regarding demand remaining strong over the next two to three years.

"While we've seen some stability for CRL's RMS business in the US, we don't see a catalyst for meaningful volume growth. Higher outsourcing penetration can support some growth for toxicology but we believe penetration rates are fairly mature," the Barclays report added.

Latest Ratings for CRL

DateFirmActionFromTo
Feb 2021Morgan StanleyMaintainsOverweight
Feb 2021Morgan StanleyMaintainsOverweight
Feb 2021Truist SecuritiesMaintainsBuy

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

 

Related Articles (CRL)

View Comments and Join the Discussion!

Posted-In: Barclays Douglas TsaoAnalyst Color Downgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com